 NDA supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study NDA includes detailed safety analysis of 2,477 patients with nearly 1,000 patients on study drug for 4 years MORRISTOWN, N.J., Dec. 23, 2022 GLOBE NEWSWIRE Intercept Pharmaceuticals, Inc. Nasdaq: ICPT, a biopharmaceutical company focused on ... The post Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis d... 